Nature Biotechnology
15, 737 - 740 (1997)
doi:10.1038/nbt0897-737
Minnesota's biotechnology portfolioTodd R. Nelson1
& Andrea H. Lauber2
1Todd R. Nelson is a senior fellow at Mayo Clinic/Medical Foundation, department of laboratory medicine and pathology, divisions of clinical molecular genomics, clinical biochemistry and immunology (nels0@mayo.edu)
2Andrea H. Lauber is a project manager/biotechnology specialist with Mayo Medical Ventures, Mayo Foundation, 200 First St. SW, Rochester, MN 55905 (lauber.andrea@mayo.edu) A well-diversified biotechnology portfolio, strong financial community, and excellence in technology transfer position Minnesota for continued expansion.
REFERENCES
- Blumenthal, D., et al. 1996. Relationships between academic institutions and industry in the life sciences. N. Engl. J. Med. 334: 368−373. | Article | PubMed | ISI | ChemPort |
- Blumenthal, D., et al. 1986. University Industry research relationships in biotechnology: Implications for the university. Science 232: 1361−1366. | PubMed | ISI | ChemPort |
- Stevens, A.J. 1993.Testimony to US Department of Commerce Hearing on the Bayh-Dole Act, Washington, DC, October 1993.
- Massing, D.E. 1996. A Five Year Summary of Technology Licensing Performance for US and Canadian Academic and Nonprofit Institutions, and Patent Management Firms. Association of University Technology Managers Inc., Norwalk, CT.
- Haber, E. 1996. Industry and the university. Nature Biotechnology 14: 441−442. | PubMed | ISI | ChemPort |
|
